Active, Not Recruiting
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread - CA224-048
Zaktualizowano:
14 wrzesień, 2023
|
ClinicalTrials.gov
Etap
Płeć
Zakres wieku
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1 - Available tumor tissue for biomarker analysis - Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1 Exclusion Criteria: - Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease - Participants with a history of interstitial lung disease (ILD) / pneumonitis - Prior malignancy active within the previous 3 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer Other protocol defined inclusion/exclusion criteria could apply